Form 4: Madrigal CEO Sells Shares Under 10b5-1 Plan

Madrigal Pharmaceuticals' President and CEO, William John Sibold, sold 7,616 shares of common stock for approximately $3.05 million through a pre-arranged 10b5-1 trading plan.

Summary

• William John Sibold, President and CEO, and Director of Madrigal Pharmaceuticals, Inc. (MDGL), reported a sale of common stock.
• The transaction occurred on August 21, 2025.
• A total of 7,616 shares of common stock were sold in two separate transactions.
• The first transaction involved 6,485 shares sold at a weighted average price of $400.0347 per share, with prices ranging from $400.00 to $400.50.
• The second transaction involved 1,131 shares sold at a weighted average price of $401.0003 per share, with prices ranging from $401.00 to $401.01.
• Total proceeds from these sales amounted to approximately $3,047,757.
• Following these transactions, William John Sibold beneficially owns 109,753 shares of Madrigal Pharmaceuticals common stock.
• These sales were executed automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
• fluv ],
• positives
• negatives": [ "Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Sentiment

Score: 5

Explanation: The sale was conducted under a pre-arranged 10b5-1 trading plan, which typically indicates a planned liquidity event (e.g., diversification, tax planning) rather than a reaction to new, negative information. This makes the sentiment neutral, as it's not a discretionary sale.

Risks

• Potential for negative investor perception regarding insider selling, despite the pre-arranged nature of the transaction.

Future Outlook

This filing, a Form 4, reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing is a standard disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitor activities. It reflects an individual executive's pre-planned stock sale.

Stakeholder Impact

• Shareholders might perceive insider selling negatively, though the 10b5-1 plan mitigates concerns about immediate negative sentiment as it indicates a pre-planned transaction.

Key Dates

Recommendation

The reported transaction is a pre-scheduled sale under a Rule 10b5-1 plan, which is a common practice for executives for diversification or liquidity purposes and does not necessarily reflect a change in the company's fundamental outlook or the insider's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Madrigal Pharmaceuticals, MDGL, insider trading, Form 4, stock sale, CEO, Director, 10b5-1 plan, William John Sibold